Contact the Editorial Desk

Editorial correspondence

Ascent Peptides welcomes correspondence on the research record: a citation we have rendered inaccurately, a regulatory status that has changed, or a peer-reviewed study about CJC-1295, Sermorelin or Tesamorelin that should be added to the references page. Corrections that improve the accuracy of the digest are the most useful messages we receive, and they are read carefully.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That structure lets us verify a proposed change against the source quickly.

Editorial mailbox: editors@ascentpeptides.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Ascent Peptides is a literature digest, not a clinic or a vendor, so we cannot:

• Advise on, recommend, or comment on human use of any peptide discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a particular research finding applies to a particular person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Answer requests from athletes subject to anti-doping rules about using these compounds, given that all three are prohibited in sport.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.